“Varun Dwaraka from diagnostics company TruDiagnostic in Lexington, Kentucky, led a randomized controlled trial involving 108 people with HIV-associated lipohypertrophy, a condition characterized by excess fat accumulation and accelerated cellular aging. Half the participants received weekly Ozempic injections for 32 weeks, while the other half received a placebo.

The researchers used epigenetic clocks to assess biological aging – sophisticated tools that identify patterns of DNA methylation, chemical tags that affect gene activity and shift predictably with age. These patterns can be accelerated or slowed by lifestyle factors, meaning biological age can differ significantly from chronological age.

‘Those on semaglutide became, on average, 3.1 years biologically younger by the end of the study,’ Dwaraka reported. The placebo group showed no significant change in biological age over the same period.”

From MedPath.